ABBVIE INC. (ABBV) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 20...
ABBVIE INC. (ABBV) currently trades at a P/E ratio of 125.38 (historical range: 57.08–181.34, median: 98.12), placing it at the 72th percentile — above its historical average, P/S ratio of 7.26 (range: 5.26–7.51, 97th percentile — expensive relative to its history), EV/EBITDA of 128.04 (range: 27.83–132.07, 97th percentile).
Over the historical period (2024-08-30 to 2026-08-28), ABBVIE INC.'s P/E ratio has expanded by 89% over the observed period (from an average of 73.4 to 139.0).
ABBVIE INC. appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 125.38 | 57.08 | 98.12 | 181.34 | 72th | above its historical average |
| P/S Ratio | 7.26 | 5.26 | 6.28 | 7.51 | 97th | expensive relative to its history |
| EV/EBITDA | 128.04 | 27.83 | 46.53 | 132.07 | 97th | expensive relative to its history |
| FCF Yield | 0.01 | 0.00 | 0.02 | 0.06 | 15th | expensive relative to its history |